

Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

Provider alert

Blue Cross commercial and BCN commercial

Category: Pharmacy
Date posted: Sept. 27, 2024

2025 coverage change for GLP-1 drugs to treat obesity

Beginning Jan. 1, 2025, or on the group's 2025 health coverage renewal date, Blue Cross Blue Shield of Michigan and Blue Care Network will no longer cover prescriptions for glucagon-like peptide-agonist drugs used for weight loss, including Saxenda[®], Wegovy[®] and Zepbound[®].

This change applies to Blue Cross and BCN commercial members of fully insured large groups with a prescription drug plan. If members decide to use these medications for weight loss in 2025, after the group's renewal date, they'll be responsible for the full cost. Affected members will receive a letter prior to this change.

Some self-funded groups have removed coverage for these medications.

Additional information

Members can visit the websites for Saxenda, Wegovy and Zepbound to determine if they offer discount coupons. These medications may also be offered at a discount through GoodRx.

<u>Subscribe</u> to Provider Alerts Weekly, a weekly email with a list of links to the previous week's provider alerts.